About pralsetinib
RET kinase inhibitor
Used for
- Treats advanced RET fusion-positive non-small-cell lung cancer.
- Treats advanced RET-altered thyroid cancer when radioactive iodine is unsuitable or ineffective.
Usual adult dose
400 mg by mouth once daily on an empty stomach; continue until progression or unacceptable toxicity.
Common side effects
- High blood pressure
- Low blood cell counts
- Constipation
- Liver enzyme changes
Important warnings
- Can cause serious lung inflammation, bleeding, or liver injury.
- Monitor blood pressure and blood counts during treatment.
- Avoid pregnancy; effective contraception is needed during treatment and afterward.
- Avoid strong CYP3A inhibitors or inducers when possible.
Pregnancy
May harm an unborn baby. Human pregnancy data are limited; avoid use during pregnancy.
Breastfeeding
Do not breastfeed during treatment and for one week after the last dose.
Interactions
- Strong CYP3A inhibitors can raise pralsetinib levels.
- Strong CYP3A inducers can lower pralsetinib levels.
- Acid-reducing medicines may lower absorption; follow product-specific timing instructions.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.